MSB 5.85% $1.09 mesoblast limited

Great post @kervio, this is a continuation of our conversation...

  1. 118 Posts.
    lightbulb Created with Sketch. 113
    Great post @kervio, this is a continuation of our conversation the other day (you have explained beautifully).

    The question the analysis raises (or unknown at this point) is whether or not the SOC improvements in survival rates will also be seen in the Rem-L group?

    • Based on Mt Sinai I think the figs were 83% survival (17% mortality) for Rem-L.
    • The SOC has moved from 88% mortality to 35% mortality
    • If we get only (for example) a 25% improvement in our mortality rate due to the general SOC improvement
    • The new (Rem-L) mortality percentage would 12.75% (down from 17%) ie only 9 deaths in 68 achieving the p<0.0001 (or overwhelming efficacy at the 45% readout)

    I don't know whether the general improvements in SOC would translate into an improvement in both groups, it is however, a potential upside for earlier overwhelming efficacy.

    Maybe someone else could answer that?
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.09
Change
0.060(5.85%)
Mkt cap ! $1.238B
Open High Low Value Volume
$1.03 $1.10 $1.02 $6.406M 6.038M

Buyers (Bids)

No. Vol. Price($)
2 313712 $1.08
 

Sellers (Offers)

Price($) Vol. No.
$1.09 100000 1
View Market Depth
Last trade - 16.10pm 17/05/2024 (20 minute delay) ?
Last
$1.08
  Change
0.060 ( 5.29 %)
Open High Low Volume
$1.03 $1.10 $1.02 928883
Last updated 15.59pm 17/05/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.